Skip to main content
. Author manuscript; available in PMC: 2021 Jun 19.
Published in final edited form as: ACS Chem Biol. 2020 Apr 30;15(6):1630–1641. doi: 10.1021/acschembio.0c00264

Figure 5. SPAM peptide reduces clinical and cross-reactive anti-PD-L1 antibody binding to CHO-hPD-L1 cells.

Figure 5.

Cells were pretreated with SPAM peptide, SPAM-scramble peptide, WL-12 or BMS-202 followed by treatment with Fluorescein-labeled antibody and flow cytometry. (A) CHO-hPD-L1 cells labeled with Fluorescein-Atezolizumab. (B) CHO-hPD-L1 cells labeled with Fluorescein-Avelumab. (C) CHO-hPD-L1 cells labeled with Fluorescein-16373 antibody. (D) CHO-mPD-L1 cells labeled with Fluorescein-16373 antibody. (E) CHO-hPD-L1 cells labeled with Fluorescein-16377 antibody. (F) CHO-mPD-L1 cells labeled with Fluorescein-16373 antibody. Each measurement was carried out in triplicate and error bars show the standard deviation of the mean. One-way ANOVA with Dunnett’s multiple comparison’s test p value < 0.05 (*), < 0.01 (**), < 0.001 (***).